BioCentury | Nov 27, 2014
Clinical News

Astellas: Data show fidaxomicin's efficacy, cost savings

...treatment for CDI in 2012. Data were presented Wednesday at the Federation of Infection Societies (FIS...
BioCentury | Oct 21, 2013
Clinical News

Aubagio teriflunomide: Additional Phase III data

...Expanded Disability Status Scale (EDSS) and patient-reported fatigue as assessed by the Fatigue Impact Scale (FIS...
BioCentury | Apr 29, 2013
Clinical News

Aubagio teriflunomide: Phase III data

...Expanded Disability Status Scale (EDSS) and patient-reported fatigue as assessed by the Fatigue Impact Scale (FIS...
BioCentury | Oct 22, 2012
Clinical News

Aubagio teriflunomide: Additional Phase III data

...the Expanded Disability Status Scale (EDSS), patient-reported fatigue as assessed by the Fatigue Impact Scale (FIS...
BioCentury | Sep 17, 2012
Company News

Critical Outcome Technologies, Fabbrica Italiana Sintetici (F.I.S.) S.p.A. deal

Critical Outcome and F.I.S.'s Delmar Chemical Inc. company partnered to discover and develop small molecules against targets that are a "specific interest to major pharmaceutical companies." Critical Outcome will use its CHEMSAS drug discovery technology,...
BioCentury | Jun 4, 2012
Clinical News

Aubagio teriflunomide: Phase III data

...the Expanded Disability Status Scale (EDSS), patient-reported fatigue as assessed by the Fatigue Impact Scale (FIS...
BioCentury | Jan 2, 2012
Clinical News

Aubagio teriflunomide: Phase III data

...any cause; annualized relapse rate (ARR), patient-reported fatigue as assessed by the Fatigue Impact Scale (FIS...
BioCentury | Jul 19, 1999
Tools & Techniques

Manufacturing a new approach to HIV

...a target to the two targets and three drug classes now in use against HIV. FIs...
Items per page:
1 - 8 of 8
BioCentury | Nov 27, 2014
Clinical News

Astellas: Data show fidaxomicin's efficacy, cost savings

...treatment for CDI in 2012. Data were presented Wednesday at the Federation of Infection Societies (FIS...
BioCentury | Oct 21, 2013
Clinical News

Aubagio teriflunomide: Additional Phase III data

...Expanded Disability Status Scale (EDSS) and patient-reported fatigue as assessed by the Fatigue Impact Scale (FIS...
BioCentury | Apr 29, 2013
Clinical News

Aubagio teriflunomide: Phase III data

...Expanded Disability Status Scale (EDSS) and patient-reported fatigue as assessed by the Fatigue Impact Scale (FIS...
BioCentury | Oct 22, 2012
Clinical News

Aubagio teriflunomide: Additional Phase III data

...the Expanded Disability Status Scale (EDSS), patient-reported fatigue as assessed by the Fatigue Impact Scale (FIS...
BioCentury | Sep 17, 2012
Company News

Critical Outcome Technologies, Fabbrica Italiana Sintetici (F.I.S.) S.p.A. deal

Critical Outcome and F.I.S.'s Delmar Chemical Inc. company partnered to discover and develop small molecules against targets that are a "specific interest to major pharmaceutical companies." Critical Outcome will use its CHEMSAS drug discovery technology,...
BioCentury | Jun 4, 2012
Clinical News

Aubagio teriflunomide: Phase III data

...the Expanded Disability Status Scale (EDSS), patient-reported fatigue as assessed by the Fatigue Impact Scale (FIS...
BioCentury | Jan 2, 2012
Clinical News

Aubagio teriflunomide: Phase III data

...any cause; annualized relapse rate (ARR), patient-reported fatigue as assessed by the Fatigue Impact Scale (FIS...
BioCentury | Jul 19, 1999
Tools & Techniques

Manufacturing a new approach to HIV

...a target to the two targets and three drug classes now in use against HIV. FIs...
Items per page:
1 - 8 of 8